编者按:越来越多的数据显示，新辅助免疫疗法在根除 dMMR/MSI直肠肿瘤方面具有很好的疗效。在NICHE试验中，大多数早期dMMR/微卫星不稳定性结肠癌患者表现出完全病理反应，而几乎所有患者都有主要病理反应。
中新网武汉7月10日电 (马芙蓉 聂文闻 杨瑞溪)武汉协和医院10日召开新闻发布会介绍，该院胃肠肿瘤多学科团队创新提出“短程放疗序贯化疗联合免疫新辅助疗法”治疗局部晚期直肠癌。随机对照研究结果显示，该治疗模式病理完全缓解率达39.8%。
南都记者从中山大学附属第六医院获悉，该院骆衍新、禹汇川团队在直肠癌临床诊疗领域发布一项新的研究结果，强调了多模态评估在直肠癌新辅助免疫治疗中的重要作用，据了解，按照此方向实施的新方案有望提高低位直肠癌患者的保肛率。
参考文献:Yang Z， Gao J， Zheng J， Han J， Li A， Liu G， Sun Y， Zhang J， Chen G， Xu R， Zhang X， Liu Y， Bai Z， Deng W， He W， Yao H， Zhang Z. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer : a multi-center phase 2 study. Signal Transduct Target Ther. 2024 Mar 11;
43岁的王先生（化名）因反复便血到一家医院咨询检查。经过肠镜检查及病理活检，确诊为直肠癌。自己年纪不大，最近几年也戒烟限酒，为啥还会得癌症呢？接下来该怎么治呢？带着种种疑问，王先生家人经过多方面了解，慕名找到了山东省立第三医院肿瘤三科主任张慎贵。
nine were female， and the mean age at diagnosis was 65 years. T stage was as follows: T1- 1， T2 - 11， T3 - 7. Eighteen pts completed at least 5 cycles of neoadjuvant Ctx and 16/19 underwent LE. Negative margins were achieved in 79% ， meeting our primary endpoint . Ten were downstaged， and complete pathological response was achieved in 5/16 of pts who underwent LE. Four pts did not meet the primary endpoint . Of these， three were salvaged ， and one died of infection . All 16 who underwent LE completed CXRT. Of the 15 pts with successful OP at a median follow-up of 25.5 months， no local recurrences have been reported and 1 pt with lung nodules below the threshold for metastases at study entry ultimately developed clear lung metastases. Median DFS was not reached.?
潮新闻客户端 记者 吴朝香 通讯员 张冰清7月4日，张先生（化名）准时来到浙江大学医学院附属邵逸夫医院（下简称：浙大邵逸夫医院）肛肠外科潘洋滔医生的诊间，慎重地递上一本“排便日记”，里面详细记录了他一周的排便情况。
